Almirall is seeking to find novel targets and concepts in the treatment of dermatological diseases. The company’s AlmirallShare open innovation platform is calling for proposals from October 10, 2018 to February 28, 2019 from universities, research centers, start-ups, biotechs and pharma companies all over the world with an interest in pharmaceutical R&D. 

Targets of interest may be proteins or nucleic acids whose function can be modulated by a small molecule or biological therapy that have a scientific rationale in a dermatological disease. Concepts may be mechanisms, pathways, or cell players not previously linked to a disease of interest. 

Scientists from target organizations are invited to submit their proposals. All submitted projects are evaluated in a pre-defined period of time and those that are accepted are eligible for a research grant up to 100,000€. Selected proposals may also benefit from scientific support from Almirall’s team, access to Almirall’s technology platforms and pharmacological tools to assist them on target validation, and specialised advice for intellectual property matters, if requested. 

Since its launch in September 2017, AlmirallShare has drawn the attention of Scientists from universities, research centers and start-ups interested on dermatological research. About 380 scientists from all continents have subscribed to the platform and over 120 proposals have been received to date. A selection of innovative ideas were accepted and they are currently being developed.